Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

A novel biomechanical analysis of gait changes in the MPTP mouse model of Parkinson's disease.

Geldenhuys WJ, Guseman TL, Pienaar IS, Dluzen DE, Young JW.

PeerJ. 2015 Aug 11;3:e1175. doi: 10.7717/peerj.1175. eCollection 2015.

2.

Methyl Yellow: A Potential Drug Scaffold for Parkinson's Disease.

Geldenhuys WJ, Kochi A, Lin L, Sutariya V, Dluzen DE, Van der Schyf CJ, Lim MH.

Chembiochem. 2014 Jul 21;15(11):1591-1598. doi: 10.1002/cbic.201300770. Epub 2014 Jul 8.

3.

Impact of circadian nuclear receptor REV-ERBĪ± on midbrain dopamine production and mood regulation.

Chung S, Lee EJ, Yun S, Choe HK, Park SB, Son HJ, Kim KS, Dluzen DE, Lee I, Hwang O, Son GH, Kim K.

Cell. 2014 May 8;157(4):858-68. doi: 10.1016/j.cell.2014.03.039.

4.

Dimebon attenuates methamphetamine, but not MPTP, striatal dopamine depletion.

Geldenhuys WJ, Darvesh AS, Dluzen DE.

Neurochem Int. 2012 Jun;60(8):806-8. doi: 10.1016/j.neuint.2012.03.013. Epub 2012 Mar 28.

PMID:
22710395
5.

Markers associated with testosterone enhancement of methamphetamine-induced striatal dopaminergic neurotoxicity.

Buletko AB, Dluzen DE, McDermott JL, Darvesh AS, Geldenhuys WJ.

Neurotoxicol Teratol. 2012 May-Jun;34(3):338-43. doi: 10.1016/j.ntt.2012.03.003. Epub 2012 Apr 1.

PMID:
22521941
6.

Nomifensine alters sex differences in striatal dopaminergic function.

Poth LS, O'Connell BP, McDermott JL, Dluzen DE.

Synapse. 2012 Aug;66(8):686-93. doi: 10.1002/syn.21554. Epub 2012 Apr 17.

PMID:
22389194
7.

Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease.

Bourque M, Dluzen DE, Di Paolo T.

Front Neuroendocrinol. 2012 Apr;33(2):169-78. doi: 10.1016/j.yfrne.2012.02.003. Epub 2012 Mar 1. Review.

PMID:
22387674
8.

Sex and temporally-dependent effects of methamphetamine toxicity on dopamine markers and signaling pathways.

Bourque M, Dluzen DE, Di Paolo T.

Neuropharmacology. 2012 Jun;62(7):2363-72. doi: 10.1016/j.neuropharm.2012.02.009. Epub 2012 Feb 21.

PMID:
22369785
9.

Markers associated with sex differences in methamphetamine-induced striatal dopamine neurotoxicity.

Dluzen DE, McDermott JL, Bourque M, Di Paolo T, Darvesh AS, Buletko AB, Laping NJ.

Curr Neuropharmacol. 2011 Mar;9(1):40-4. doi: 10.2174/157015911795017399.

10.

Structure-activity relationship and docking studies of thiazolidinedione-type compounds with monoamine oxidase B.

Carroll RT, Dluzen DE, Stinnett H, Awale PS, Funk MO, Geldenhuys WJ.

Bioorg Med Chem Lett. 2011 Aug 15;21(16):4798-803. doi: 10.1016/j.bmcl.2011.06.060. Epub 2011 Jun 21.

PMID:
21742494
11.

Parity decreases methamphetamine-induced striatal dopaminergic perturbation.

Dluzen DE.

Neurochem Int. 2011 Aug;59(2):101-3. doi: 10.1016/j.neuint.2011.04.005. Epub 2011 Jun 14.

PMID:
21693145
12.

The effect of freezing and extraction upon striatal dopaminergic function.

Dluzen DE.

J Neurosci Methods. 2011 May 15;198(1):23-8. doi: 10.1016/j.jneumeth.2011.02.031. Epub 2011 Mar 12.

PMID:
21392526
13.

Sex differences in methamphetamine toxicity in mice: effect on brain dopamine signaling pathways.

Bourque M, Liu B, Dluzen DE, Di Paolo T.

Psychoneuroendocrinology. 2011 Aug;36(7):955-69. doi: 10.1016/j.psyneuen.2010.12.007. Epub 2011 Jan 13.

PMID:
21236583
14.

Male/Female differences in neuroprotection and neuromodulation of brain dopamine.

Bourque M, Dluzen DE, Di Paolo T.

Front Endocrinol (Lausanne). 2011 Sep 30;2:35. doi: 10.3389/fendo.2011.00035. eCollection 2011.

15.

Age-related changes in nigrostriatal dopaminergic function in heterozygous mutant dopamine transporter knock-out mice.

Dluzen DE, Ji J, McDermott JL.

Neurosci Lett. 2010 May 31;476(2):66-9. doi: 10.1016/j.neulet.2010.04.004. Epub 2010 Apr 9.

PMID:
20382201
16.

Relationships among gender, age, time, and temperature in methamphetamine-induced striatal dopaminergic neurotoxicity.

Dluzen DE, McDermott JL, Darvesh AS.

Neuroscience. 2010 Jun 2;167(4):985-93. doi: 10.1016/j.neuroscience.2010.02.076. Epub 2010 Mar 6.

PMID:
20211701
17.

Effects of a novel dopamine uptake inhibitor upon extracellular dopamine from superfused murine striatal tissue.

Geldenhuys WJ, Bezuidenhout LM, Dluzen DE.

Eur J Pharmacol. 2009 Oct 1;619(1-3):38-43. doi: 10.1016/j.ejphar.2009.08.012. Epub 2009 Aug 15.

PMID:
19686731
18.

Genetic alteration in the dopamine transporter differentially affects male and female nigrostriatal transporter systems.

Ji J, Bourque M, Di Paolo T, Dluzen DE.

Biochem Pharmacol. 2009 Dec 1;78(11):1401-11. doi: 10.1016/j.bcp.2009.07.004. Epub 2009 Jul 15.

PMID:
19615345
19.

Neuroprotective actions of sex steroids in Parkinson's disease.

Bourque M, Dluzen DE, Di Paolo T.

Front Neuroendocrinol. 2009 Jul;30(2):142-57. doi: 10.1016/j.yfrne.2009.04.014. Epub 2009 May 3. Review.

PMID:
19410597
20.

Sex differences in dopamine- and vesicular monoamine-transporter functions.

Dluzen DE, McDermott JL.

Ann N Y Acad Sci. 2008 Oct;1139:140-50. doi: 10.1196/annals.1432.010.

PMID:
18991858
21.

Testosterone enhances dopamine depletion by methamphetamine in male, but not female, mice.

Lewis C, Dluzen DE.

Neurosci Lett. 2008 Dec 19;448(1):130-3. doi: 10.1016/j.neulet.2008.10.011. Epub 2008 Oct 7.

PMID:
18852023
22.

Differences in reserpine-induced striatal dopamine output and content between female and male mice: implications for sex differences in vesicular monoamine transporter 2 function.

Dluzen DE, Bhatt S, McDermott JL.

Neuroscience. 2008 Jul 17;154(4):1488-96. doi: 10.1016/j.neuroscience.2008.04.051. Epub 2008 May 2.

PMID:
18515015
23.

Gender differences in methamphetamine use and responses: a review.

Dluzen DE, Liu B.

Gend Med. 2008 Mar;5(1):24-35. Review.

PMID:
18420163
24.

Sex differences in striatal dopaminergic function within heterozygous mutant dopamine transporter knock-out mice.

Ji J, Dluzen DE.

J Neural Transm (Vienna). 2008 Jun;115(6):809-17. doi: 10.1007/s00702-007-0017-0. Epub 2008 Jan 15.

PMID:
18197357
25.

Aging and sex differences in striatal dopaminergic function.

McDermott JL, Dluzen DE.

Neuroscience. 2007 Oct 26;149(2):401-8. Epub 2007 Sep 1.

PMID:
17900817
26.

Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity.

Bourque M, Liu B, Dluzen DE, Di Paolo T.

Biochem Pharmacol. 2007 Nov 1;74(9):1413-23. Epub 2007 Jul 14.

PMID:
17825264
27.
28.

Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.

Liu B, Dluzen DE.

Clin Exp Pharmacol Physiol. 2007 Jul;34(7):555-65. Review.

PMID:
17581209
29.

Protective effects of ginsenoside Rg2 against glutamate-induced neurotoxicity in PC12 cells.

Li N, Liu B, Dluzen DE, Jin Y.

J Ethnopharmacol. 2007 May 22;111(3):458-63. Epub 2006 Dec 20.

PMID:
17257792
30.

Estrogen, testosterone, and methamphetamine toxicity.

Dluzen DE, McDermott JL.

Ann N Y Acad Sci. 2006 Aug;1074:282-94. Review.

PMID:
17105924
31.

Gender differences in Parkinson's disease.

Haaxma CA, Bloem BR, Borm GF, Oyen WJ, Leenders KL, Eshuis S, Booij J, Dluzen DE, Horstink MW.

J Neurol Neurosurg Psychiatry. 2007 Aug;78(8):819-24. Epub 2006 Nov 10.

32.

Sex differences in methamphetamine-evoked striatal dopamine of mice are reversed by nomifensine.

Kunnathur V, Shemisa K, Liu B, Salvaterra TJ, Dluzen DE.

Neurotoxicol Teratol. 2006 Sep-Oct;28(5):557-62. Epub 2006 Jul 28.

PMID:
16978834
35.

Testosterone modulation of striatal dopamine output in orchidectomized mice.

Shemisa K, Kunnathur V, Liu B, Salvaterra TJ, Dluzen DE.

Synapse. 2006 Oct;60(5):347-53.

PMID:
16838357
36.
37.

Differential protective properties of estradiol and tamoxifen against methamphetamine-induced nigrostriatal dopaminergic toxicity in mice.

D'Astous M, Mickley KR, Dluzen DE, Di Paolo T.

Neuroendocrinology. 2005;82(2):111-20. Epub 2006 Jan 27.

PMID:
16446547
39.

Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Xu K, Xu Y, Brown-Jermyn D, Chen JF, Ascherio A, Dluzen DE, Schwarzschild MA.

J Neurosci. 2006 Jan 11;26(2):535-41.

40.

Estrogen, testosterone, and gender differences.

Dluzen DE.

Endocrine. 2005 Aug;27(3):259-67. Review.

PMID:
16230782
41.

Unconventional effects of estrogen uncovered.

Dluzen DE.

Trends Pharmacol Sci. 2005 Oct;26(10):485-7. Review.

PMID:
16122814
42.

Dopamine transporter function differences between male and female CD-1 mice.

Bhatt SD, Dluzen DE.

Brain Res. 2005 Feb 28;1035(2):188-95. Epub 2005 Jan 22.

PMID:
15722058
44.

Gender differences in modulatory effects of tamoxifen upon the nigrostriatal dopaminergic system.

Dluzen DE, Mickley KR.

Pharmacol Biochem Behav. 2005 Jan;80(1):27-33.

PMID:
15652377
45.
46.
47.

Age-related changes in nigrostriatal dopaminergic function are accentuated in +/- brain-derived neurotrophic factor mice.

Dluzen DE, McDermott JL, Anderson LI, Kucera J, Joyce JN, Osredkar T, Walro JM.

Neuroscience. 2004;128(1):201-8.

PMID:
15450367
49.

Dopamine transporter as a marker of neuroprotection in methamphetamine-lesioned mice treated acutely with estradiol.

D'Astous M, Gajjar TM, Dluzen DE, Di Paolo T.

Neuroendocrinology. 2004;79(6):296-304. Epub 2004 Jul 9.

PMID:
15249736
50.

Supplemental Content

Loading ...
Support Center